Skip to main content

Advertisement

Table 2 Patient demographic characteristics

From: Content validation of the SF-36v2® health survey with AL amyloidosis patients

  Concept Elicitation Cognitive Debriefing
Demographic Information Mean (Range), years
Age 57.2 (41–76) 63.30 (39–74)
Time since diagnosis 2.3 (0.33–8) 4.18 (0.50–18)
Time from first symptom to diagnosis 2 (0.25–4)
  N (%)
Gender
 Male 6 (60) 5 (50)
 Female 4 (40) 5 (50)
Region of U.S. Residence
 South 4 (40) 0 (0)
 Midwest 3 (30) 0 (0)
 East Coast 2 (20) 10 (100)
 West Coast 1 (10) 0 (0)
Education
 Less than Bachelor’s degree 4 (40) 5 (50)
 Bachelor’s degree 3 (30) 2 (20)
 Post-graduate 3 (30) 3 (30)
Multiple Organ Involvement
 Yes 5 (50) 4 (40)
 No 5 (50) 6 (60)
Organs Affecteda
 Heart 6 (60) 5 (50)
 Kidney 5 (50) 6 (60)
 Gastrointestinal Tract 3 (30) 0 (0)
 Nervous System 2 (20) 1 (10)
 Liver 0 (0) 1 (10)
 Bladder 0 (0) 1 (10)
Remission Status
 Full Remission 5 (50) 2 (20)
 Partial Remission 1 (10) 3 (30)
 Not in Remission 4 (40) 4 (40)
 Unsure 0 (0) 1 (10)
Current Treatmenta
 Bortezomib (Velcade) 4 (40)
 Dexamethasone 3 (30)
 Doxycycline 2 (20)
 Lenalidomide (Revlimid) 2 (20)
 Other 2 (20)
  1. aPatients were able to select more than one option, so percentages exceed 100
  2. – indicates that data were not collected for this variable